Celgene (CELG)
Celgene develops cancer and immune-inflammatory related drugs.
With a market cap of $33.5 billion, it's among the most valuable companies in
Investor's Business Daily's 234-stock Medical-Biomedical/Biotech group.
On Nov.
9 Celgene announced positive results from an early-stage study of its new
Abraxane drug to treat pancreatic cancer.
The biotech's Earnings Per Share (EPS) jumped 26% last quarter to $1.29. It's posted
double-digit profit growth every quarter for more than four years.
No comments:
Post a Comment